De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
Language English Country United States Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
Grant support
00023736
Ministerstvo Zdravotnictví Ceské Republiky
00669806
Ministerstvo Zdravotnictví Ceské Republiky
LX22NPO5102
Ministerstvo Školství, Mládeže a Tělovýchovy
MUNI/A/1558/2023
Ministerstvo Školství, Mládeže a Tělovýchovy
PubMed
38317312
DOI
10.1002/ajh.27229
Knihovny.cz E-resources
- MeSH
- Blast Crisis drug therapy MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive * drug therapy MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Tyrosine Kinase Inhibitors * MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Protein Kinase Inhibitors MeSH
- Tyrosine Kinase Inhibitors * MeSH
Overall survival of patients classified according to the European LeukemiaNet 2020 classification. Chronic phase (CP), accelerated phase (AP), blast crisis (BC), low risk (LR), intermediate risk (IR), high risk (HR).
1st Internal Dpt General University Hospital Prague Prague Czech Republic
Central European Institute of Technology Masaryk University Brno Czech Republic
Dpt of Hemato oncology University Hospital Olomouc and Palacky University Olomouc Czech Republic
Dpt of Hemato oncology University Hospital Pilsen and Charles University Pilsen Czech Republic
Dpt of Hematooncology Faculty of Medicine University of Ostrava Ostrava Czech Republic
Dpt of Hematooncology University Hospital Ostrava Ostrava Czech Republic
Institute of Biostatistics and Analyses Brno Czech Republic
Institute of Hematology and Blood Transfusion Prague Czech Republic
See more in PubMed
Foley TH, Bennett JM, Carbone PP. Combination chemotherapy in accelerated phase of chronic granulocytic leukemia. Arch Intern Med. 1969;123:166-170.
Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
Arber DA, Orazi A, Hasserjian R, et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228.
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966-984.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-1719.
Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: a work in progress. Am J Hematol. 2023;98:1350-1353.
Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2015;30:48-56.
